Uncovering the molecular mechanisms behind disease-associated leptin variants

Ellinor Haglund, Lannie Nguyen, Nicholas Peter Schafer, Heiko Lammert, Patricia Ann Jennings, and José Nelson Onuchic

From the Center for Theoretical Biological Physics and the Departments of Physics and Astronomy, Chemistry, and Biosciences, Rice University, Houston, Texas 77005 and the Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093

Edited by Karen G. Fleming

The pleiotropic hormone leptin has a pivotal role in regulating energy balance by inhibiting hunger and increasing energy expenditure. Homozygous mutations found in the leptin gene are associated with extreme obesity, marked hyperphagia, and impaired immune function. Although these mutations have been characterized in vivo, a detailed understanding of how they affect leptin structure and function remains elusive. In the current work, we used NMR, differential scanning calorimetry, molecular dynamics simulations, and bioinformatics calculations to characterize the effects of these mutations on leptin structure and function and binding to its cognate receptor. We found that mutations identified in patients with congenital leptin deficiency not only cause leptin misfolding or aggregation, but also change dynamics in the range of leptin residues on the receptor-binding interface. Therefore, we infer that mutation-induced leptin deficiency may arise from several distinct mechanisms including (i) blockade of leptin receptor interface II, (ii) decreased affinity in the second step of leptin’s interaction with its receptor, (iii) leptin destabilization, and (iv) unsuccessful threading through the covalent loop, leading to leptin misfolding/aggregation. We propose that this expanded framework for understanding the mechanisms underlying leptin deficiency arising from genetic mutations may be useful in designing therapeutics for leptin-associated disorders.

Obesity is one of the biggest public health challenges in the world (1), often leading to inflammation and early mortality. Furthermore, obesity increases susceptibility to other diseases, such as hyperinsulinemia, advanced bone age, hypothalamic hypothryroidism, and hypogonadotrophic hypogonadism (2–4), hyperthermia and cold intolerance, and hypercorticolemia and other endocrine and metabolic abnormalities (5), which lead to failure to undergo puberty and infertility (6). Although regulation of energy expenditure is considered the primary function of leptin, it also plays a role in other physiological processes, such as cancer (7), thermogenesis, and immune function (8), as evidenced by its many sites of synthesis other than adipose tissue (9) and the many cell types other than hypothalamic cells that have leptin receptors. Many of these additional functions are yet to be fully characterized.

Control of appetite and the predisposition for obesity have been linked to 41 sites on the human genome (10). One of these genes is the pleiotropic hormone leptin (11–13), which has a pivotal role in regulating energy balance through inhibition of hunger and increased energy expenditure. Interestingly, there are genetic modifications observed in patients with congenital leptin deficiency, a form of monogenic obesity characterized by its early-age onset and marked hyperphagia (14–16).

In classic leptin deficiency, no protein or very low levels of leptin are detected in serum of patients. Recently, a new type of functional leptin deficiency has been described wherein normal to high levels of bioinactive leptin are detected in the serum of patients (17). Specifically, these leptin variants are biologically inactive due to structural alteration in the receptor-binding sites, thus decreasing the affinity for its receptor, the leptin receptor (LEP-R) (18, 19). These observations introduced a new form of effective leptin deficiency, wherein leptin is produced and secreted but functionally inactive because of impaired binding to LEP-R. Both classic and functional leptin deficiency can be treated by replacement with recombinant human leptin (17). Nevertheless, a more detailed mechanistic understanding of leptin’s biological activity and of the different modes of failure caused by disease mutations, holds great promise for enhancing leptin’s potential as a target for drug development and therapeutics.

Leptin is secreted from adipose tissue and must cross the blood–brain barrier and bind to its receptor in the hypothalamus (20) to activate the leptin signaling pathway. Additional pathways can also be activated in peripheral tissue, as the leptin

5 The abbreviations used are: LEP-R, leptin receptor; PLT, pierced lasso topology; DSC, differential scanning calorimetry; nsSNP, non-synonymous single nucleotide polymorphism; NSD, native state dynamics; RMSF, root mean square fluctuation; D3, D4, and D5, domain 3, 4, and 5, respectively; MD, molecular dynamics; HSQC, heteronuclear single quantum coherence; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol.
Uncovering the molecular mechanisms behind leptin deficiency

receptor is found on the cell surface of many organs and tissues in the body (21–25).

To activate the signaling pathway, leptin binds to the LEP-R in a sequential fashion (Fig. 1). It first makes an initial complex with the LEP-R. Once bound to leptin in a 1:1 configuration (Fig. 1B), the receptors can interact further and form a 2:2 quaternary complex (Fig. 1C) representing the core-signaling complex (26–28). Domain 3 (D3) allows for the formation of the quaternary complex that initiates signaling. Previous studies revealed that deletion of D3 completely abolished signaling (29, 30), demonstrating its integral role in formation of the quaternary complex. This is reminiscent of the role for D3 in other cytokine receptor systems, where it interacts with binding site III of the ligand already bound to another receptor chain. Once activated, the LEP-R complex signals through activation of four different signaling pathways: (i) through the Janus kinase 2 (JAK2) signaling pathway, (ii) the signal transducer and activator of transcription 3 (STAT3), (iii) the insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K), and (iv) the SH2-containing protein tyrosine phosphatase 2 (SHP2)/mitogen-activated protein kinase (MAPK) 5′-adenosine monophosphate-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) (31). Although the signaling complex between leptin and LEP-R is not yet fully understood, we can reconstruct some structural aspects of LEP-R activation based on (i) the structural data from Carpenter et al. (32), where the authors crystallize domains 4 and 5 (D4 and D5) of LEP-R together with an antibody; (ii) EM data from Mancour et al. (26), showing the full initial binary complex between leptin and LEP-R and (iii) more recent work by Moharana et al. (27), who used SAXS experiments to investigate the activated quaternary configuration (Fig. 1C).

Recently, we discovered that the topology of leptin is not trivial, but instead, leptin has a “knotlike” configuration under oxidizing conditions (see the supporting information). Part of the polypeptide chain is threaded through the 50-residue covalent loop that is closed by the disulfide bridge formed between the two cysteines (Fig. 1A), resulting in a pierced lasso topology (PLT) (33). This PLT is not unique to leptin, as PLTs have been found in more than 300 proteins within the Protein Data Bank (33–39). Interestingly, we showed that the PLT is important to leptin’s biological activity, as the threaded topology introduces conformational dynamics in sites far removed from the disulfide bridge. In particular, the PLT influences the dynamics of residues that are important for receptor interaction and leptin signaling (33, 35, 36, 39), thereby lowering the affinity for the LEP-R in its reduced form (33, 35). The reduced form of leptin, missing the PLT, shows decreased affinity for the LEP-R receptor (33, 35). Furthermore, the PLT has a profound effect on protein stability, as breaking the disulfide bond decreases the global stability from 3.4 to 1.8 kcal/mol (33). This is a larger perturbation of the global stability than is expected from the loss of a typical disulfide bridge that is not involved in a PLT.

Given the importance of the PLT to the biological activity of leptin, the following question then arises. Is the threading event affected in the case of the disease-associated mutations identified in leptin, or can these proteins still thread into a WT-like knotlike conformation?

The recent discovery of purely functional leptin deficiency in addition to classical leptin deficiency in serum indicates that the biological function of leptin may be disrupted in multiple different ways. At the genetic level, congenital leptin deficiency is caused by homozygous mutations of either the leptin or LEP-R genes (40). In the leptin gene, 13 disease-associated mutations implicated in obesity have been found to date (see Fig. S1) (18, 19, 41–52). The affected residues are located throughout the structure of leptin, suggesting, again, that different mechanisms may be responsible for the effects of different mutations. Several in vivo studies of disease-associated leptin variants have been conducted, but the mechanisms that lead to defective leptin are not yet fully understood. It has been suggested that leptin’s disulfide bridge is crucial for biological activity and that disruption is the cause of disease (44, 45, 48), but do conditions presented in patients with leptin deficiency simply result from the loss of a single disulfide bridge?

To elucidate the structural and functional origins of congenital leptin deficiencies that result from different homozygous mutations in leptin, we constructed and purified the seven known, full-length variants of leptin that are implicated in proatheropathogenic diseases. These variants were probed using NMR and differential scanning calorimetry (DSC) experiments together with molecular dynamics (MD) simulations and bioinformatics techniques to evaluate the mutational effects on stability, dynamics, and solubility of the native state. As expected from previously published results (4, 41, 42, 47, 53–55), all proteins express well, suggesting that lack of protein synthesis is probably not the cause of disease. Our results, combined with previous biochemical, biological, and medicinal studies (16, 18, 19, 41–52), suggest that leptin deficiency can arise from multiple mechanisms, including (i) blockage of receptor interface through binding site II in leptin, interacting with domains 4 and 5 of the receptor to initiate a nonsignaling LEP-R complex, (ii) modifications of the affinity for domain 3 on the receptor through binding site III in leptin, perturbing the formation of the quaternary complex, leading to impaired signaling; (iii) destabilization of the native biologically active state that could occur through the loss of salt bridges or the disulfide bridge leading to an unthreaded topology and possibly degradation/clearance from serum; and (iv) unsuccessful threading through the covalent loop that might lead to protein misfolding and/or protein aggregation.

When leptin is destabilized or cannot reach the native PLT conformation, it may be either quickly degraded or may aggregate, both of which would result in impaired secretion and an absence of leptin in serum. Our data indicate that each of these mechanisms probably contributes to pathological behavior in some of the full-length disease-associated leptin variants.

Results

Known disease mutations

The gene encoding leptin is located on chromosome 7q31.3, where the translated portion of the NCBI reference sequence is NM_000230.2 (56). A sequence alignment of leptin homologs is shown as a sequence logo plot in Fig. S1 (bottom). The plot presents the level of conservation with the one-letter code for.
each amino acid. The size of the letter indicates the level of conservation; the larger the letter the more conserved is the residue. Five of the 13 disease-associated mutations identified in leptin are deletion or nonsense mutations expressing truncated versions of the protein: I14del (48, 49), Q28Tfs*23 (52), Q34stop (50), G112Vfs*15 (42), and L140Gfs*10 (48) (Fig. S1, top). Two mutations (R84stop (41, 43, 47) and V124E (47)) have been found in murine leptin, where R84stop is another truncated version, whereas V124E is a single point mutation that results in a full-length protein. All seven of the above-mentioned leptin variants except V124E are probably degraded quickly and cleared from serum due to the decrease in protein stability or inability to fold into native-like structures. Therefore, none of these mutations are considered explicitly in this study (see supporting information, “Disease-associated mutations identified in leptin”).

In the current work, we study all known full-length variants of leptin that lead to leptin deficiency, namely L51S (55), D79Y (17, 19), N82K (17, 18, 46, 51), R84W (4, 44), C96Y (45), S120C (45), and V124E (47) (Figs. 1A and 2). Each of these mutations is systematically analyzed below.

WT leptin

Naturally occurring leptin has two tryptophan residues (Trp100 in loop III and Trp138 at the C terminus of H9251 D). The W100E variant of leptin (pseudo-WT) was made for crystallization purposes and has since been shown to have WT-like biological activity (57). The W100E variant is present in all of our disease-causing variants in the current work. The pseudo-WT protein forms soluble dimers/oligomers as well as visible aggregates in solution. Some of these native-like aggregates can revert to the monomeric form upon dilution or decreased tem-
temperature, whereas some are irreversible aggregates that fall out of solution (58). Both types of aggregation occur during the refolding process during purification in vitro and are removed from the samples through size-exclusion chromatography and ultracentrifugation (see “Materials and methods”).

Characterization methods for disease-associated leptin variants

To evaluate the effects of disease-associated mutations on the native structure of leptin, we conducted heteronuclear single quantum coherence (HSQC) NMR experiments (Fig. 3) together with native state dynamics (NSD) simulations for the fully folded variants using all-atom structure-based models (see “Materials and methods” for more details of the model (59, 60)). Additionally, kinetic unfolding simulations of the pseudo-WT protein were performed to characterize the threading mechanism and to study potential kinetic traps on the folding pathway using all-atom structure-based models. DSC thermoanalytical experiments were used to quantify the mutational effects on protein stability (Table 1) combined with the predictions of stability changes upon mutations using mCSM (61) to compute the predicted stability changes for mutations where a DSC signal was not observed. The prediction tool mCSM provides quantitative estimates of the distribution of stability changes induced by mutations through a novel approach to predicting the effects of mutation in proteins using graph-based signatures (61). In addition to domain stability, we calculated predicted solubility changes between WT leptin and all variants of leptin obtainable via a nonsynonymous SNP (nsSNP) using CamSol (Fig. 4) (62).

Location and biophysical character of disease-associated mutations in the structure of leptin

Disease-associated mutations in leptin are scattered throughout the structure and are not confined to one specific region (Fig. 1A and Fig. S1, top). Residue Leu51 is located in a conserved region at the N terminus of H9251B (Fig. S1), in close proximity to the disulfide bridge. The aliphatic side chain is buried and orients the backbone amide for hydrogen bonding with the carbonyl of Gly145, thereby tethering the threaded helical hairpin (H9251B and half of H9251A) to the covalent loop (Fig. 2A). This contact makes an important polar contact with Gly145 (deep blue dashed line), in close proximity to the covalent loop (yellow sticks). This contact tethers the threaded element to the covalent loop, keeping it in place. The disulfide bridge is represented in yellow, indicating residue Cys96.

Residue Asp79 is located in the middle of H9251A and is part of the conserved region interacting with the LEP-R through binding site II in leptin (19) (Figs. S1 and S2). More importantly, both D79Y and N82K interact with D4 and D5 on the LEP-R. C, the side chain of Arg44 is oriented toward the core of the protein interacting with Glu62 and Asp55, whereas Asn62, represented as a red stick, is oriented toward the solvent and interacts with LEP-R. D, Val124 is sandwiched in between the two proposed sites of binding site III in leptin (28). Introducing a negatively charged glutamic acid at this position could have a dramatic effect on receptor interaction. Residue Ser120 is part of the receptor-binding site III and is located above Val124.

Residue Asn82 is located in the middle of H9251C and is part of a moderately conserved region interacting with the LEP-R through binding site II in leptin (19) (Figs. S1 and S2). The negatively charged side chain of Asp79 forms a salt bridge with Arg20 in H9251B that will break upon mutation to a noncharged tyrosine (Fig. 2B). Additionally, a tyrosine at this position could block the receptor from binding, as the side chain is larger and bulkier than the side chain of aspartic acid (Fig. S2). Additionally, substituting a charged side chain with a hydrophobic side chain could have dramatic effects on receptor binding.

Residue Asp79 is located in the middle of H9251C and is part of the conserved region interacting with the LEP-R through binding site II in leptin (19) (Figs. S1 and S2). The negatively charged side chain of Asp79 forms a salt bridge with Arg20 in H9251B that will break upon mutation to a noncharged tyrosine (Fig. 2B). Additionally, a tyrosine at this position could block the receptor from binding, as the side chain is larger and bulkier than the side chain of aspartic acid (Fig. S2). Additionally, substituting a charged side chain with a hydrophobic side chain could have dramatic effects on receptor binding.

Residue Asn82 is located in the middle of H9251C and is part of the conserved region interacting with the LEP-R through binding site II in leptin (19) (Figs. S1 and S2). The negatively charged side chain of Asp79 forms a salt bridge with Arg20 in H9251B that will break upon mutation to a noncharged tyrosine (Fig. 2B). Additionally, a tyrosine at this position could block the receptor from binding, as the side chain is larger and bulkier than the side chain of aspartic acid (Fig. S2). Additionally, substituting a charged side chain with a hydrophobic side chain could have dramatic effects on receptor binding.
ation at this position is permitted as long as the polarity of the side chain is kept intact (Fig. S1, bottom). Residue Arg\textsuperscript{84} is located in the middle of αC oriented toward the core of the protein, centered in the back of the receptor-binding site II. Sequence alignments show that this region is moderately conserved (Fig. S1, bottom), suggesting that the mutation R84W is allowable and should not interfere with the LEP-R interaction (Fig. 2C). Upon mutation to tryptophan, the salt bridge formed with the side chain of Asp\textsuperscript{55} will break. This mutation may also affect the polar contact formed with Gln\textsuperscript{62} due to the introduction of a bulky side chain (Fig. 2C).

Finally, R84W substitutes a charged, partially exposed residue with a hydrophobic residue, thereby possibly affecting the solubility of the folded state and its aggregation propensity (Table 2).

Residue Cys\textsuperscript{96} connects loop III in leptin with the C-terminal cysteine under oxidizing conditions (Figs. 2 and 3A), forming a PLT (see supporting information) (33, 35). The sequence alignments (Fig. S1, bottom) show that both cysteine residues are absolutely conserved (33, 39). Hence, mutating Cys\textsuperscript{96} to any other residue will break the disulfide bond and, consequently, disrupt the threaded topology, shifting the folding equilibrium toward a denatured state in leptin (33, 35). In this way, C96Y is analogous to the reduced version of the WT protein, where the disulfide bridge is chemically modified, as neither protein can form the native disulfide bridge. It has already been shown that this will lead to a detrimental loss of global stability of the protein and decreased biological activity (33, 35).

Residue Ser\textsuperscript{120} is located at the end of the loop between αC and αD, in a moderately conserved region of the protein (Fig. 2C). Sequence alignments show that this region is moderately conserved (Fig. S1, bottom), suggesting that the mutation S120C is allowable and should not interfere with the LEP-R interaction (Fig. 2C). Upon mutation to cysteine, the salt bridge formed with the side chain of Glu\textsuperscript{131} will break.

---

**Table 1**

| Name         | T\textsubscript{m} °C |
|--------------|------------------------|
| WT (W100E)   | 58.7                   |
| L51S         | ND\textsuperscript{a}  |
| D79Y         | 59.9                   |
| N82K         | ND                     |
| R84W         | 72.0                   |
| C96Y         | ND                     |
| S120C        | 71.9                   |
| V124E        | 58.7                   |

\textsuperscript{a} The raw data are provided in Fig. S3.

\textsuperscript{b} ND, not determined.

---

Figure 3. Structural analyses of the disease-associated mutations identified in leptin through NMR HSQCS. The 1H-15N HSQCs are shown for the leptin variants as a representation of the structural changes in solution at 25 °C upon mutation, where the pseudo-WT protein is represented in black and the overlaid mutations are represented in red.
Uncovering the molecular mechanisms behind leptin deficiency

Figure 4. Predicted changes in solubility of the folded and denatured states of leptin upon mutation using CamSol (62). The predicted solubility changes for mutations in leptin are plotted against the background of all point mutations that can arise from nsSNPs. Negative values correspond to a predicted decrease in solubility. Positive values correspond to a predicted increase in the solubility compared with the WT protein. Solubility changes for all unique amino acid mutations that can arise from a nsSNP are shown as large blue dots. Disease-causing mutations are highlighted with larger blue dots. The density contour indicates the density of predicted solubility changes in a particular area of the plot and is provided for clarity. A high density of mutations (red) is found in the regions of the plot corresponding to mutations that are predicted to slightly increase (positive values) or decrease (negative values) the solubility. Lower-density regions are indicated in orange and yellow. Both the R84W and D79Y mutations are found in the very-low-density (white) region of the plot, indicating that they are outliers with respect to their predicted decrease in the solubility of both the folded and unfolded states of leptin.

S1, bottom). It has two polar contacts: one with the backbone of Val123 and one with Val124 at the N terminus of αD, rigidifying and stabilizing loop IV (Fig. 2D). It has been proposed that Ser120 together with Thr121 is part of the receptor interphase III, binding to D3 of LEP-R, where binding site III is involved in the formation of the active quaternary complex (53).

Residue Val121 is located at the N terminus of αD in a moderately conserved region of the protein. Sequence alignments show that leucine can also be observed at this position, indicating that there is space to fit a larger side chain at this position (Fig. S1, bottom). However, introducing a negatively charged side chain could affect receptor-binding site III in leptin, as residue 124 is sandwiched in between the two suggested regions that interact with D3 in LEP-R (Fig. 2D) (28).

Structural evaluation

To evaluate the structural and dynamic perturbations of the mutations, we performed NMR HSQC experiments together with NSD in silico simulations for the proteins that showed fully folded spectra by NMR. The HSQCs revealed that four of the seven mutations tested fold into native-like structures exhibiting only minor shifts compared with the pseudo-WT protein, which are expected for a single point mutation (Fig. 3). The HSQC spectra of D79Y, N82K, S120C, and V124E coincide well with the pseudo-WT spectrum (Fig. 3). The spectrum of S120C shows a small population of aggregated protein, presumably due to dimerization via the formation of a free cysteine on the surface of leptin. Native state dynamics simulations were conducted for all leptin variants that appeared to be folded according to NMR (Fig. 5). All of the folded protein variants except V124E exhibit WT-like native state dynamics in their free forms (Fig. 5A), indicating that the dynamic motions are not affected by these mutations. In the case of V124E, however, the mutation introduces larger fluctuations (compared with the WT protein) around residues 33–43 and 103–127 both in the free form and when bound to D4D5, thus affecting regions that are important in receptor interactions and biological activity (Fig. 5B).

In contrast to the well-folded variants, the HSQC backbone spectral dispersions are markedly abolished for the three remaining proteins, with only between ~1.3 and 0.98 ppm over 1H and between ~18 and 20 ppm over 15N dimensions. R84W display the most dramatic shifts, indicating a nearly complete denaturation or an aggregated protein (Fig. 3). The HSQCs of L51S and C96Y show a spectrum typical of a protein that exhibits partially denatured/partially folded states (Fig. 3), where the main population seems to be denatured. There are, however, some peaks that overlap with the pseudo-WT protein, indicating that there might be a small population of folded protein in these samples. However, higher-resolution NMR data are necessary to make further conclusions regarding the native structures of these proteins.

Biophysical characterization of stability

DSC measurements were performed to evaluate the mutational effects on protein stability. The four variants that appeared to have native-like structures by NMR (D79Y, N82K, S120S, and V124E) have apparent melting temperatures the same as or higher than that of the pseudo-WT protein (Table 1). The other leptin variants (L51S, C96Y, and R84W), which showed poorly dispersed NMR spectra, do not exhibit an unfolding transition under any conditions that we tested. This suggests that L51S, C96Y, and R84W are denatured and/or aggregated at room temperature. Because the C96Y variant is analogous to the reduced form of WT leptin, where the disulfide bridge is chemically removed, we expect that the loss of the disulfide bridge through mutation has a similar effect on protein stability as reducing the pseudo-WT protein, which results in a destabilization of ∆ΔG = −1.6 kcal/mol (33). As there are no clear unfolding signals from DSC experiments for L51S and R84W either, we used the web tool mCSM to estimate the stability changes upon mutation (61). L51S is predicted to be significantly destabilized, with a predicted ∆ΔG of ~2.882 kcal/mol, whereas R84W is predicted to be only marginally destabilized (∆ΔG of ~0.649 kcal/mol).

Aggregation during purification

Leptin is purified from inclusion bodies in vitro, which involves initially denaturing the protein in its reduced state. After the first purification step, both reducing and oxidizing GSH are used to allow the disulfide bridge to be made and broken upon refolding, increasing the probability of successful threading of the covalent loop or refolding without the disulfide bridge. Ultracentrifugation and an extra size-exclusion step are used to eliminate aggregated and/or oligomeric species. In the
case of R84W, no protein was obtained using this standard method. Therefore, reducing agent alone was used to purify this protein. The failure to obtain R84W via the standard purification indicates that this particular variant cannot refold at all in its oxidized state, whereas in the reduced state, purification of some protein is possible. The different behavior of the reduced and oxidized forms of R84W points to an involvement of the PLT in the misfolding of the oxidized state, where threading of the covalent loop must occur in order to reach the native topology. Arg84 is part of the threaded element, and substitution by

### Table 2

Biophysical properties of the disease-associated mutations identified in leptin

| Name       | pI<sup>a</sup> | Net charge at pH 7.0 | Original amino acid | Mutated amino acid | Sequence conservation<sup>b</sup> | Position |
|------------|---------------|----------------------|---------------------|--------------------|------------------------------------|----------|
| WT         | 6.16          | −2.2                 | Hydrophobic         | Negative           | Low                                | Loop III |
| pswt (W100E)| 5.76          | −2.2                 | Hydrophobic         | Polar              | High                               | αB-loop II |
| L51S       | 5.76          | −2.2                 | Hydrophobic         | Negative           | High                               | αC       |
| D79Y       | 6.16          | −2.2                 | Negative            | Hydrophobic        | High                               | αC       |
| N82K<sup>c</sup> | 6.16 | −2.2 | Polar | Positive | Moderate | αC |
| R84W<sup>d</sup> | 5.41 | −2.2 | Positive | Hydrophobic | Moderate | αC |
| C96Y       | 5.78          | −3.1                 | Special             | Hydrophobic        | High                               | Loop III |
| S120C<sup>e</sup> | 5.76 | −2.2 | Special | Hydrophobic | Moderate | Loop IV |
| V124E<sup>f</sup> | 5.76 | −2.2 | Hydrophobic | Negative | Moderate | αD |

<sup>a</sup> A theoretical pI calculated for each mutation using ExPASy Bioinformatics Resources Portal (https://web.expasy.org/compute_pi/).

<sup>b</sup> Supported by the sequence alignment in Fig. S1 (bottom).

<sup>c</sup> Residue 82 is usually an asparagine but can also be a threonine (polar), as is found in some leptin homologs.

<sup>d</sup> Residue 84 is usually an arginine but can also be a leucine (hydrophobic), as is found in some leptin homologs, indicating that a hydrophobic tryptophan residue should not cause disease, as the size agrees with an arginine and the sequence allows for a hydrophobic substitution. Nonetheless, a tryptophan residue at this position may block threading through the covalent loop due to its large “sticky” side chain that can interact with the other tryptophans in the covalent loop (i.e. Trp<sup>100</sup> and Trp<sup>138</sup> in the WT protein).

<sup>e</sup> Residue 120 is usually a serine but can also be a threonine (polar), as is found in some leptin homologs. Adding a reactive cysteine to the protein might lead to dimerization, as residue 120 is at the surface and thus free to interact with other leptin molecules to form an intermolecular disulfide bond under oxidizing conditions in the cell.

<sup>f</sup> Residue 124 is usually a valine but can also be a leucine (hydrophobic), as is found in some leptin homologs.

**Figure 5.** The backbone RMSF of residues in leptin is plotted against the amino acid sequence index for several leptin variants. The WT protein is represented in black, and the disease-associated variants are shown in red. A and B, plots of RMSF for the free protein (A) and protein bound to D4 and D5 (B) (32). The receptor interaction sites are highlighted with ellipses, where receptor-binding site II is represented in blue and binding site III in cyan.
Uncovering the molecular mechanisms behind leptin deficiency

Figure 6. Relative prevalence of amino acid types in the threaded element for threaded and nonthreaded leptin homologs. In threaded sequences, tryptophan shows up about half as often in the threaded element as it does in the sequence as a whole. In nonthreaded sequences (defined as sequences that lack one or both cysteines at positions 96 and 146), tryptophan appears twice as much in the part of the sequence that corresponds to the threaded element as it does in the sequence as a whole. Across all amino acid types, this difference in relative prevalence between threaded and nonthreaded sequences is largest for tryptophan. The mean values and S.D. (shown as error bars) were obtained by bootstrapping (see "Materials and methods" for details).

tryptophan may result in steric clashes during loop threading. MD simulations with an all-atom structure-based model indicate that Arg138 forms transient nonnative interactions during threading with Trp138 as well as W100E (Fig. 6). When position 84 is mutated to tryptophan, these nonnative interactions would be stabilized and might trap the protein in a partially threaded configuration. Taken together, it seems plausible that the extreme aggregation propensity of R84W under oxidizing conditions is due to unsuccessful threading through the closed covalent loop. Additionally, having tryptophan in the threaded element compared with the sequence as a whole is disfavored in leptin homologs only when the PLT is formed (see Fig. 6 and “Materials and methods”). This bioinformatic analysis serves as further evidence that having a tryptophan in the threaded element may prevent or slow down threading, which is consistent with our experience when trying to purify the R84W variant in reducing and oxidizing conditions.

For R84W refolded under reducing conditions, our HSQC spectrum also shows little dispersion, and most of the native peaks are missing. The low dispersion in NMR and the lack of an observable DSC transition, together with previously published results (4, 44), could indicate that R84W, even when prepared under reducing conditions, is not natively folded but denatured or aggregated. We used the CamSol algorithm to investigate solubility changes upon mutation in leptin (62). R84W is predicted to be much less soluble than the WT, with a higher propensity to aggregate even from its folded state (Fig. 4), consistent with the observations of aggregation from the experiments. Although the R84W mutation is predicted to be only modestly destabilizing to the native structure by mCSM, mCSM does not take into account the possibility that a tryptophan at position 84 may prevent threading of the covalent loop and thereby block access to the native PLT conformation. Whether the R84W mutation contributes to aggregation either by preventing threading, reducing the solubility of the folded state, or both, remains to be definitively determined. The currently available data suggest that both mechanisms are possible. Interestingly, CamSol also predicts that the D79Y mutation significantly reduces the solubility of leptin (Fig. 4). We have not observed any indication of aggregation for D79Y over the time scale of our experiments. However, this does not preclude the possibility of aggregation on biologically relevant time scales.

Discussion

The World Health Organization has designated obesity a global epidemic, and the underlying mechanisms are not yet completely understood. Obesity is the result of a combination of social, environmental, and genetic factors. It leads to metabolic syndrome, depression, and type-2 diabetes (63). Research into the genetics of human obesity has become increasingly sophisticated with respect to molecular technologies, biostatistics, and efficient design strategies. However, the molecular mechanisms behind genetic obesity and leptin deficiency remain elusive.

To date, 13 disease-associated mutations in leptin have been identified in mice and humans (Fig. S1) (18, 19, 41–52). In the current work, we investigate structural perturbations and the importance of the PLT in mutations leading to congenital leptin deficiency. Our results, considered in the light of the currently available literature, suggest that the disease-associated mutations in leptin may lead to leptin deficiency by at least four different mechanisms: (i) blockage of receptor interface through binding site II in leptin, interacting with D4 and D5 of the LEP-R initiating a nonsignaling complex; (ii) modifications of the affinity for D3 on the LEP-R through binding site III in leptin, perturbing the formation of the quaternary complex and leading to impaired signaling; (iii) destabilization of the native state through the loss of salt bridges and/or the disulfide bridge leading to an unthreaded topology, probably leading to degradation/clearance from serum; and (iv) unsuccessful threading through the covalent loop that might lead to protein misfolding and/or a loss of solubility of the folded leptin structure.

We hope that these classifications will serve as a framework for understanding the possible ways in which mutations in leptin can give rise to leptin deficiency. To our knowledge, no such framework has yet been proposed. This framework should be revised when more structural, biological, and biophysical data of leptin variants become available.

Mutations affecting receptor-binding sites II and III in leptin, through mechanism (i) or (ii)

Our NMR experiments show that four of the seven mutations in the current work fold into WT-like structures with maintained or higher thermal stability, namely D79Y, N82K, S120C, and V124E (Fig. 3 and Table 1). Interestingly, inspection of the LEP-R complex together with previously published results indicate that all of these leptin variants are involved in receptor binding (28). Niv-Spector et al. (18) showed that Asp79...
Uncovering the molecular mechanisms behind leptin deficiency

and Asn^N2 are part of receptor-binding site II, forming the interface with D4D5 (18), whereas Ser^D20 together with Thr^D21 has been proposed to form part the binding interface of D3 (18, 53, 64). When mutated, D79Y and N82K leptin variants fail to dock with the LEP-R, acting as a leptin antagonist blocking leptin signaling (Fig. S2) (16). Both D79Y and N82K have been studied in human cells and were shown to have a decreased affinity for the LEP-R and cannot initiate signaling for this reason (18, 19).

In contrast, for V124E, Hong et al. (47) performed co-immunoprecipitation analysis showing that the variant was indeed interacting with the LEP-R in hypothalamus through receptor-binding site II. However, to our knowledge, no further studies investigating the second step of receptor binding and signaling for V124E have been conducted. Indeed, both S120C and V124E have the same affinity for the LEP-R as the WT protein without being able to initiate leptin signaling in the cells (45, 47). This suggests that neither of these two mutations affects receptor-binding site II in leptin and the formation of the initial nonsignaling complex.

The locations of Ser^D20 and Val^D24 further suggest that both S120C and V124E interfere with the subsequent formation of the active quaternary complex (Fig. 2D). In the case of V124E, our MD simulations support this conclusion further by showing increased fluctuations in binding site III, both for the free V124E variant and bound to D4D5 of LEP-R in a model of the initial complex (Fig. 5). As residue Val^D24 is sandwiched between the two proposed regions forming binding site III in leptin, it is plausible that substitution of a larger glutamic acid residue will perturb the local dynamics. The additional effect of introducing a negative charge is not considered in our all-atom structure-based model but can also be expected to be disruptive. Additionally, Mancour et al. (26) showed that mutated LEP-R (i.e. where they introduced a mutation in residue 370 (L370A) in D3) abolishes leptin binding via receptor-binding site III. Thus, we infer that perturbation of receptor-binding site III on leptin and/or perturbation of D3 on the LEP-R leads to an incomplete formation of the 2:2 quaternary complex.

According to our NMR and DSC experiments, D79Y, N82K, S120C, and V124E fold into native-like structures with comparable or increased thermal stability compared with the pseudo-WT protein (Fig. 3 and Table 1). These results agree with the previously published observations that D79Y, N82K, and V124E are biologically inactive proteins detected in serum of patients who nonetheless suffer from leptin deficiency (17, 18, 47, 51). Interestingly, no protein has been detected in serum of patients with the S120C mutation (45, 47). The impaired secretion in the case of S120C could be caused by the added reactive cysteine forming intermolecular disulfide bridges in the cell under oxidizing conditions. It is also possible that S120C is secreted, but no protein is found in serum of patients depending on the immunoassay used for leptin detection, as was shown in the case of N82K (17–19, 46, 51, 65). In the case of N82K, the conventional assay for immunoreactive leptin (a radioactive immunoassay and ELISA and/or Western blotting) failed to detect leptin in serum of patients (46, 65), whereas the new immunoassay developed by Kratzsch et al. (66) is able to recognize the functionally relevant receptor-binding complex with leptin.

Taken together, we suggest that proteopathies induced by these four leptin variants (D79Y, N82K, S120C, and V124E) arise due to alterations in the binding pocket of binding sites II and II in leptin according to mechanism (i) disrupting the formation of the initial 1:1 nonsignaling complex and/or mechanism (ii) disrupting the formation of the 2:2 active quaternary complex (Fig. 8). In the case of S120C, it seems possible that this functional disruption is combined with a separate depletion of serum levels of the inactive protein.

Mutations destabilizing or misfolding the protein through mechanism (iii) and/or (iv)

None of the leptin variants containing the mutation L51S, C96Y, or R84W exhibit a thermal unfolding transition from a native to a denatured protein in our DSC measurements or show a native-like HSQC spectrum. This indicates that these proteins are denatured, aggregated, or both. Our bioinformatic studies show that both the L51S and C96Y mutations decrease the global stability of leptin compared with the pseudo-WT protein, thus shifting the folding equilibrium toward the denatured state (Figs. 4 and 5). According to the CamSol algorithm (Fig. 4), L51S and C96Y are soluble if folded, but the lowered stability of the native state is sufficient to explain their absence from serum. R84W, on the other hand, is predicted to maintain WT-like stability (ΔG of −0.649 kcal/mol (61)) but is also predicted by CamSol to be less soluble due to interactions introduced by the partially surface-exposed tryptophan. Interestingly, an arginine-to-tryptophan substitution is one of the most common disease-causing mutations (67).

In leptin, the effect of the mutation R84W could depend on the added complexity of threading a tryptophan though the covalent loop under oxidizing conditions, as no protein is obtained from the standard method of purification. Only when refolded under reducing conditions is a small concentration of protein produced during purification, suggesting that the linear (unthreaded) form of R84W can fold. Yet the protein obtained via purification in the reduced state also aggregates once the disulfide bridge is closed under the oxidizing conditions used in the NMR experiments (Fig. 3), consistent with CamSol’s prediction of reduced solubility in the folded state (Fig. 4). Upon purification with both reducing and oxidizing GSH, severe aggregation occurs, indicating further impaired refolding of oxidized R84W when the covalent loop is closed by the disulfide bridge. Steric hindrance during threading by the bulky tryptophan residue added to the threaded element may prevent successful folding. According to our MD simulations of pseudo-WT leptin (Fig. 7), residue 84 forms nonnative interactions with the other tryptophan, Trp^E36, located on the covalent loop. With a tryptophan introduced in position 84, these interactions threaten to trap the protein in a partially threaded misfolded configuration. This effect could be even more pronounced in vivo, as leptin naturally has another tryptophan residue in the covalent loop, Trp^D100, which had been substituted in the pseudo-WT to help crystallization. This observed misfolding, in conjunction with the formation of aggregates as the protein is refolded in the reduced state and the disulfide bridge
is reoxidized (Fig. 8), could contribute to leptin deficiency in patients carrying the R84W mutation.

Taken together, the inability to fold, due to a loss in protein stability, in the case of L51S and C96Y explains why there is no leptin observed in serum of patients, as denatured proteins are degraded and not secreted from the cell (4, 55). R84W finally shows so many defects that it is hard to attribute its pathological effects to a single cause. But there is evidence that failure to thread into the PLT topology under oxidizing conditions is contributing to the severe aggregation observed in R84W.

Conclusions

We propose that mutations identified in patients with congenital leptin deficiency can cause proteinopathies through at least four different mechanisms. Some of the full-length disease-associated leptin variants studied here can fold into stable, native-like structures and still lead to disease through impaired function, as seen in Fig. 8. Existing data about receptor binding and our own simulation results indicate that signaling may fail either at the stage of the initial binary complex between leptin and LEP-R or at the stage of the active quaternary complex formed from two copies of the binary complex. As the currently available published data on LEP-R binding have focused on formation of the initial complex, these studies may not have picked up on deficiencies that are only apparent at the latter stage of receptor interaction and the formation of the quaternary complex and therefore report WT-like affinities for some variants. Additional
studies of the later stages of signaling would be valuable to test our interpretation.

Some leptin variants lose function due to a loss of stability of the native state, misfolding, and aggregation. The resulting phenotypes correspond to classical leptin deficiency, wherein patients lack detectable levels of leptin in serum. There is clear support for loss of stability in two cases (L51S and C96Y). Because one of them (C96Y) involves loss of the covalent disulfide bridge, functional impairment analogous to reduced WT protein is expected as an additional consequence, but the loss of stability presumably takes effect before the defective binding can be realized. The last mutation (R84W) produces such severe aggregation under different conditions that a multiplicity of causes may contribute to loss of function. Our unfolding simulations indicate that misfolding due to disrupted threading of the covalent loop of the PLT is a possible factor.

In summary, our data, considered in the light of available literature on leptin variants, support at least four different mechanisms of disease causation by mutations in leptin (Fig. 8).

Materials and methods

Molecular biology and protein purification

Pseudo-WT leptin was cloned into a pET3a vector and transformed into competent BL21 Escherichia coli cells. Protein expression was induced by the addition of 1 mM isopropyl-1-thio-β-D-galactopyranoside, and cells were harvested and purified from inclusion bodies as described (33). When purifying R84W, one can only use reducing agent to produce a very small amount of protein. Normally, we use both reducing and...
oxidized GSH during the refolding process, allowing the disulfide bridge to be made and broken. This increases the probability of successful threading of the covalent loop or folding without the disulfide bridge. If both reducing and oxidizing agents are used, no soluble protein will be observed as R84W visibly aggregates upon refolding.

All proteins were run through a size-exclusion column after refolding to eliminate oligomeric/misfolded species. Protein purity was determined by SDS-PAGE, and fractions containing the monomeric protein were collected. Disease mutations were constructed using QuikChange mutagenesis, and primers were ordered from Stratagene.

NMR HSQC experiments

\(^{1}\text{H}-^{15}\text{N}\) HSQC and HSQC TROSY experiments were collected on a 600-MHz Bruker magnet equipped with a Cryo-Probe at 25 °C, using a 50 mM BisTris buffer at pH 6.3 and 10% D\textsubscript{2}O. The final protein concentration was 100 \textmu M for all proteins except C96Y. Due to its propensity to form intermolecular disulfide bonds, 20 \textmu M TCEP was added to the buffer used in the C96Y experiments, and the concentration was maintained at 10 \textmu M. To avoid protein aggregation and/or degradation after purification, all NMR experiments were conducted immediately after size-exclusion chromatography and buffer exchange of the leptin variants.

Both HSQC and HSQC-TROSY experiments were collected at different temperatures and different protein concentrations for proteins that did not display native-like spectra at 25 °C. S120C was measured under oxidizing conditions. An overlay of the HSQCs collected at 25 °C is represented in Fig. 3.

DSC thermoanalytical experiments

The advantage of using a DSC assay over chemical denaturation in this study is the reduced incubation time and faster measurements. DSC also uses much smaller sample sizes at lower protein concentrations, which is important in this project, as many of the mutated proteins are hard to purify in significant amounts due to their propensity to aggregate. To avoid misinterpretations of disassociation of dimeric/oligomeric species as unfolding transitions, we plotted the \(T\textsubscript{m}\) for the lowest protein concentration tested (0.1 mg/ml; Table 1 and Fig. S3).

All measurements were collected under oxidizing conditions, except in the case of C96Y, as leptin is secreted and circulates in blood under oxidizing conditions. A Malvern MicroCal VP-Capillary DSC system equipped with a 130-\mu l capillary reaction cell (Tantalum) was used to collect the thermal denaturation transition for all samples. 400 \mu l of sample was pipetted into a 96-well plate and tested with a scan rate of 60 °C/h with a temperature range from 20 to 90 °C using a 10-s filter. Protein concentrations tested were between 0.1 and 0.5 mg/ml in a 20 mM MES buffer at pH 6.3.

In silico conformational dynamics

All-atom structure-based simulations (59, 60) were performed to characterize the NSD of mutations demonstrating a native-like fold in the current work, both in their free and bound forms. The bound structure of the WT protein docked to D4 and D5 of the receptor was taken from Carpenter et al. (Protein Data Bank code 3V6O (32)), and leptin mutations were generated in PyMOL. Simulation inputs, containing all individual heavy atoms, were prepared from the structures using the SMOG version 2 (68) package, with a customized template to account for the disulfide link. A covalent bond, represented by a harmonic potential, was placed between the two cysteine sulfur atoms, whereas tertiary interactions between the two cysteine residues were dropped. To capture the assumed locally destabilizing effects of the mutations, tertiary interactions formed by the respective mutated residues were deleted. All other native tertiary interactions are represented by stabilizing contact potentials in the model, in accordance with the principle of minimal frustration. All systems were simulated in the native state at a reduced temperature of \(T/T\textsubscript{*} = 0.83\), using an adapted version of the GROMACS software package. (The reference temperature \(T\textsubscript{*}\) is close to the folding temperature due to the construction of the model.) Four independent runs were performed for each case, each for 120 ns of simulation time for the unbound proteins and for 280 ns for the receptor-bound ones. Dynamics in the native state were characterized as root mean square fluctuation (RMSF) around the mean configuration. All discussed mutation effects are much larger than the error bars. For the pseudo-WT protein, 180 additional unfolding runs were performed, each over 10 ns of simulation time at a temperature of \(T/T\textsubscript{*} = 1.17\), which is above the folding temperature of the system. All 180 runs unfolded and unthreaded during the simulations, and no significant (re)threading occurred. The mechanism was characterized by computing the number of native contacts at every step and by using the PyLasso software to determine the degree of unthreading in each configuration. A pseudo-free energy landscape plotted for these two coordinates indicates that unfolding precedes unthreading, which finally occurs in the context of an unstructured chain with a low number of native contacts. 147 runs (82%) unthreaded via a slipknotting mechanism, which is the dominating pathway for leptin (33, 35). Plugging of the covalent loop was found in the remaining cases. To study nonnative interactions formed by residue Arg\textsuperscript{84} during unthreading, first those frames were selected from the slipknotting runs where a residue near Arg\textsuperscript{84} was placed in the plane of the covalent loop according to PyLasso. All of these structures were then aligned by fitting their loop configuration to the native structure of the covalent loop. Histograms for the placement of residues of interest in the plane of the loop were collected, using the principal axes of the native covalent loop as coordinates.

CamSol-predicted changes in solubility

The CamSol method (68) was used to predict changes in solubility compared with WT leptin. Unlike the structurally corrected scores described previously (68), the structure-adjusted scores that we are showing here have been obtained by setting all of the “smoothing weights” (68) to 1 and by using the solvent exposure of the WT residues for the “exposure weights.” Therefore, these structure-adjusted scores are corrected for solvent exposure in the WT structure but not proximity in three-dimensional space. The change in intrinsic and structure-adjusted CamSol score upon mutation is plotted for
Uncovering the molecular mechanisms behind leptin deficiency

every point mutation that can be reached from the WT leptin sequence via a nonsynonymous SNP.

Multiple-sequence alignment of leptin homologs

Analysis of the relative prevalence of amino acid types in the threaded element of leptin homologs for threaded and nonthreaded sequences was performed as follows. We obtained the multiple-sequence alignment of leptin homologs from PFAM (69) and divided the sequences into threaded and nonthreaded sequences by looking at the positions corresponding to Cys\textsuperscript{166} and Cys\textsuperscript{146} in WT leptin. Sequences with cysteines in both of these positions were considered threaded, and all other sequences were considered nonthreaded. Note that sequences in the alignment that do not have cysteines at those positions also do not have cysteines in nearby positions, so the classification of threaded and nonthreaded sequences would not depend on subtle changes to the alignment. Of a total of 279 sequences in the PFAM alignment of leptin homologs (PFAM ID PF02024, PFAM version 31.0), using the above definition, 192 are threaded and 87 are nonthreaded. Separately for the threaded and nonthreaded sets of sequences, we created 1000 new alignments of equal size (192 for threaded sequences and 87 for nonthreaded sequences) by drawing randomly from the available sequences with replacement. For each alignment, we then computed the frequency of the appearance of each amino acid type in the threaded element and in the sequence as a whole. The values reported in Fig. 6 are the ratios of these two values for each amino acid type in threaded and nonthreaded sequences. The mean (points) and S.D. (error bars) of the distributions of values obtained by computing this ratio for each amino acid type on 1000 alignments are plotted in Fig. 6. Gaps were excluded from all frequency calculations.

Author contributions—E. H. conceptualization; E. H. and L. N. formal analysis; E. H. validation; E. H. investigation; E. H. writing—original draft; E. H., L. N., N. P. S., H. L., P. A. J., and J. N. O. writing—review and editing; N. P. S. and H. L. data curation; P. A. J. and J. N. O. funding acquisition.

Acknowledgments—We thank Vivien Chau for help with cloning, Xuemei Huang for help with NMR experiments, and Verna Frasca and Muneeva Beach from Malvern for all of the help with the DSC measurements and analysis. We thank Pietro Sormanni for running the CamSol calculations. Finally, we thank Jens Danielsson and Ryan R. Cheng for helpful scientific discussions.

References

1. Ramachandrapura, S., and Farooqi, I. S. (2011) Genetic approaches to understanding human obesity. J. Clin. Invest. 121, 2080–2086 CrossRef Medline
2. Gibson, W. T., Farooqi, I. S., Moreau, M., DePaoli, A. M., Lawrence, E., O’Rahilly, S., and Truswell, R. A. (2004) Congenital leptin deficiency due to homozygosity for the A133G mutation: report of another case and evaluation of response to four years of leptin therapy. J. Clin. Endocrinol. Metab. 89, 4821–4826 CrossRef Medline
3. Ozata, M., Ozdemir, I. C., and Licinio, J. (1999) Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J. Clin. Endocrinol. Metab. 84, 3686–3695 CrossRef Medline
4. Strobel, A., Issad, T., Camoin, L., Ozata, M., and Strosberg, A. D. (1998) A leptin missense mutation associated with hypogonadism and morbid obesity. Nat. Genet. 18, 213–215 CrossRef Medline
5. Bray, G. A., and York, D. A. (1979) Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol. Rev. 59, 719–809 CrossRef Medline
6. Elias, C. F., and Purohit, D. (2013) Leptin signaling and circuits in puberty and fertility. Cell Mol. Life Sci. 70, 841–862 CrossRef Medline
7. Garofalo, C., and Sarmamaz, E. (2006) Leptin and cancer. J. Cell. Physiol. 207, 12–22 CrossRef Medline
8. Fietta, P. (2005) Focus on leptin, a pleiotropic hormone. Minerva Med. 96, 65–75 Medline
9. Margetic, S., Gazzola, C., Pegg, G. G., and Hill, R. A. (2002) Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26, 1467–1433 CrossRef Medline
10. Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., and Eckel, R. H. (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 26, 968–976 CrossRef Medline
11. Leibel, R. L., Bahary, N., and Friedman, J. M. (1990) Genetic variation and nutrition in obesity: approaches to the molecular genetics of obesity. World Rev. Nutr. Diet. 63, 90–101 CrossRef Medline
12. Leibel, R. L., Bahary, N., and Friedman, J. M. (1993) Strategies for the molecular genetic analysis of obesity in humans. Crit. Rev. Food Sci. Nutr. 33, 351–358 CrossRef Medline
13. Dickie, M. M., and Lane, P. W. (1957) Plus letter to Roy Robinson 7/7/70. Mouse News Lett. 17, 52
14. Farooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., Lechter, R. I., DePaoli, A. M., and O’Rahilly, S. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110, 1093–1103 CrossRef Medline
15. Farooqi, I. S., and O’Rahilly, S. (2014) 20 years of leptin: human disorders of leptin action. J. Endocrinol. 223, T63–T70 CrossRef Medline
16. Funcke, J. B., von Schurbein, J., Lennerz, B., Lahr, G., Debatin, K. M., Fischer-Posovskzy, P., and Wabitsch, M. (2014) Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol. Cell Pediatr. 1, 3 CrossRef Medline
17. Wabitsch, M., Pridzun, L., Ranke, M., von Schurbein, J., Moss, A., Brandt, S., Kohlsdorf, K., Moepps, B., Schaab, M., Funcke, J. B., Gierschik, P., Fischer-Posovskzy, P., Flehmig, B., and Kratzsch, J. (2017) Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency. Eur. J. Endocrinol. 176, 315–322 CrossRef Medline
18. Niv-Spector, L., Shpilman, M., Grupi, A., and Gertler, A. (2010) The obese phenotype-inducing N82K mutation in human leptin disrupts receptor-binding and biological activity. Mol. Genet. Metab. 100, 193–197 CrossRef Medline
19. Wabitsch, M., Funcke, J. B., Lennerz, B., Kuhlele-Kralh, U., Lahr, G., Debatin, K. M., Vatter, P., Gierschik, P., Moepps, B., and Fischer-Posovskzy, P. (2015) Biologically inactive leptin and early-onset extreme obesity. N. Engl. J. Med. 372, 48–54 CrossRef Medline
20. Myers, M. G., Cowley, M. A., and Münzberg, H. (2008) Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 70, 537–556 CrossRef Medline
21. Frühbeck, G. (2001) A heliocentric view of leptin. Proc. Nutr. Soc. 60, 301–318 CrossRef Medline
22. Baratta, M. (2002) Leptin: from a signal of adiposity to a hormonal mediator in peripheral tissues. Med. Sci. Monit. 8, RA282–RA292 Medline
23. Frühbeck, G. (2002) Peripheral actions of leptin and its involvement in disease. Nutr. Rev. 60, 547–555; discussion 568–584, 85–87 CrossRef Medline
24. Muir, D. M., and Lynis Dohm, G. (2002) Peripheral metabolic actions of leptin. Best Pract. Res. Clin. Endocrinol. Metab. 16, 653–666 CrossRef Medline

J. Biol. Chem. (2018) 293(33) 12919–12933 12931
45. Chekhranova, M. K., Karpova, S. K., Iatsushina, S. B., and Pankov Iu. A. (2008) [A new mutation c.422C>G (p.S141C) in homo- and heterozygous forms of the human leptin gene]. Bioorg. Khim. 34, 854 – 856 Medline

46. Mazen, I., El-Gammal, M., Abdel-Hamid, M., and Amr, K. (2009) A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient. Mol. Genet. Metab. 97, 305 – 308 CrossRef Medline

47. Hong, C. J., Tsai, P. J., Chen, C. Y., Chou, C. K., Jheng, H. F., Chuang, Y. C., Yang, C. N., Lin, Y. T., Hsu, C. W., Cheng, I. H., Chen, S. Y., Tsai, S. J., Liou, Y. J., and Tsai, Y. S. (2010) ENU mutagenesis identifies mice with morbid obesity and severe hyperinsulinemia caused by a novel mutation in leptin. PLoS One 5, e15333 CrossRef Medline

48. Fatima, W., Shakid, A., Imran, M., Manzoor, J., Hasnain, S., Rana, S., and Mahmood, S. (2011) Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int. J. Pediatr. Obes. 6, 419 – 427 CrossRef Medline

49. Saeed, S., Butt, T. A., Anwer, M., Arslan, M., and Foguel, P. (2012) High prevalence of leptin and melanocortin-4 receptor gene mutations in children with severe obesity from Pakistani consanguineous families. Mol. Genet. Metab. 106, 121 – 126 CrossRef Medline

50. Thakur, S., Kumar, A., Dubey, S., Saxena, R., Peters, A. N., and Singhal, A. (2014) A novel mutation of the leptin gene in an Indian patient. Clin. Genet. 86, 391 – 393 CrossRef Medline

51. Waibitsch, M., Funcke, J. B., von Schnurbein, J., Denzer, F., Lahr, G., Maizen, I., El-Gammal, M., Denzer, C., Moss, A., Debatin, K. M., Gierschik, P., Mistry, V., Keogh, J. M., Farooqi, I. S., Moepps, B., and Fischer-Posovszky, P. (2015) Severe early-onset obesity due to bioactive leptin caused by a p.N103K mutation in the leptin gene. J. Clin. Endocrinol. Metab. 100, 3272 – 3280 CrossRef Medline

52. Altawil, A. S., Mawlawi, H. A., Alghamdi, K. A., and Almlujain, F. F. (2016) A novel homozygous frameshift mutation in exon 2 of LEP gene associated with severe obesity: a case report. Clin. Med. Insights Pediatr. 10, 115 – 118 Medline

53. Peelman, F., Van Beneden, K., Zabeau, L., Isertenant, H., Ulrichts, P., Debatin, K. M., Gierschik, P., Mistry, V., Keogh, J. M., Farooqi, I. S., Moepps, B., and Fischer-Posovszky, P. (2016) Mapping of the leptin binding sites and design of a leptin antagonist. J. Biol. Chem. 279, 41038 – 41046 CrossRef Medline

54. Isertenant, H., Peelman, F., Defau, D., Vanderkerckhove, J., Zabeau, L., and Tavernier, J. (2004) Mapping of the interface between leptin and the leptin receptor activation revealed by complexes with wild-type and antagonist leptins. Structure 22, 866 – 877 CrossRef Medline

55. Moon, B. C., and Friedman, J. M. (1997) The molecular basis of the obese phenotype in ob/ob mice. Genomics 42, 152 – 156 CrossRef Medline

56. Rout, N., Zilberfarb, V., Camoin, L., Bonnafoius, S., Le Marchand-Brustel, Y., and Issad, T. (2004) The formation of an intrachain disulfide bond in the leptin protein is necessary for efficient leptin secretion. Biochimie (Paris) 86, 351 – 356 CrossRef Medline

57. Chekhranova, M. K., Karpova, S. K., Iatsushina, S. B., and Pankov Iu. A. (2008) [A new mutation c.422C>G (p.S141C) in homo- and heterozygous forms of the human leptin gene]. Bioorg. Khim. 34, 854 – 856 Medline

58. Mazen, I., El-Gammal, M., Abdel-Hamid, M., and Amr, K. (2009) A novel homozygous missense mutation of the leptin gene (N103K) in an obese Egyptian patient. Mol. Genet. Metab. 97, 305 – 308 CrossRef Medline

59. Hong, C. J., Tsai, P. J., Chen, C. Y., Chou, C. K., Jheng, H. F., Chuang, Y. C., Yang, C. N., Lin, Y. T., Hsu, C. W., Cheng, I. H., Chen, S. Y., Tsai, S. J., Liou, Y. J., and Tsai, Y. S. (2010) ENU mutagenesis identifies mice with morbid obesity and severe hyperinsulinemia caused by a novel mutation in leptin. PLoS One 5, e15333 CrossRef Medline

60. Fatima, W., Shakid, A., Imran, M., Manzoor, J., Hasnain, S., Rana, S., and Mahmood, S. (2011) Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int. J. Pediatr. Obes. 6, 419 – 427 CrossRef Medline

61. Saeed, S., Butt, T. A., Anwer, M., Arslan, M., and Foguel, P. (2012) High prevalence of leptin and melanocortin-4 receptor gene mutations in children with severe obesity from Pakistani consanguineous families. Mol. Genet. Metab. 106, 121 – 126 CrossRef Medline

62. Thakur, S., Kumar, A., Dubey, S., Saxena, R., Peters, A. N., and Singhal, A. (2014) A novel mutation of the leptin gene in an Indian patient. Clin. Genet. 86, 391 – 393 CrossRef Medline

63. Waibitsch, M., Funcke, J. B., von Schnurbein, J., Denzer, F., Lahr, G., Maizen, I., El-Gammal, M., Denzer, C., Moss, A., Debatin, K. M., Gierschik, P., Mistry, V., Keogh, J. M., Farooqi, I. S., Moepps, B., and Fischer-Posovszky, P. (2015) Severe early-onset obesity due to bioactive leptin caused by a p.N103K mutation in the leptin gene. J. Clin. Endocrinol. Metab. 100, 3272 – 3280 CrossRef Medline

64. Isertenant, H., Peelman, F., Defau, D., Vanderkerckhove, J., Zabeau, L., and Tavernier, J. (2004) Mapping of the leptin binding sites and design of a leptin antagonist. J. Biol. Chem. 279, 41038 – 41046 CrossRef Medline

65. Fischer-Posovszky, P., von Schnurbein, J., Moepps, B., Lahr, G., Straus, G., Barth, T. F., Kassubek, J., Mühlender, H., Möller, P., Debatin, K. M., Gierschik, P., and Waibitsch, M. (2010) A new missense mutation in the leptin gene causes mild obesity and hypogonadism without affecting T cell responsiveness. J. Clin. Endocrinol. Metab. 95, 2836 – 2840 CrossRef Medline

66. Gong, D. W., Bi, S., Pratley, R. E., and Weintraub, B. D. (1996) Genomic structure and promoter analysis of the human obese gene. J. Biol. Chem. 271, 3971 – 3974 CrossRef Medline

67. Zhang, F., Basinski, M. B., Beals, J. M., Briggs, S. L., Churgay, L. M., Clawson, D. K., DiMarchi, R. D., Furman, T. C., Hale, J. E., Hsiung, H. M., Schoner, B. E., Smith, D. P., Zhang, X. Y., Wery, J. P., and Schevitz, R. W. (1997) Crystal structure of the obese protein leptin-E100. Nature 387, 206 – 209 CrossRef Medline

68. Murphy, R., and Tsai, A. (eds) (2006) Misbehaving Proteins: Protein (Mis) Folding, Aggregation, and Stability, pp. 331 – 350, Springer, New York

69. Whitford, P. C., Noel, J. K., Giosvi, S., Schug, A., Sonnemann, K. Y., and Onuchic, J. N. (2009) An all-atom structure-based potential for proteins: bridging minimal models with all-atom empirical forcefields. Proteins 75, 430 – 441 CrossRef Medline

70. Baxter, E. L., Zuris, J. A., Wang, C., Vo, P. L., Axelrod, H. L., Cohen, A. E., Paddock, M. L., Nechushtai, R., Onuchic, J. N., and Jennings, P. A. (2013) Allotestic control in a metalloprotein dramatically alters function. Proc. Natl. Acad. Sci. U.S.A. 110, 948 – 953 CrossRef Medline

71. Pires, D. E., Ascher, D. B., and Blundell, T. L. (2014) mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics 30, 335 – 342 CrossRef Medline
62. Sormanni, P., Aprile, F. A., and Vendruscolo, M. (2015) The CamSol method of rational design of protein mutants with enhanced solubility. *J. Mol. Biol.* **427**, 478 – 490 CrossRef Medline

63. Blazer, D. G., and Hernandez, L. M. (2006) *Genes, Behavior, and the Social Environment: Moving Beyond the Nature/Nurture Debate*, National Academies Press, Washington, D. C.

64. Verploegen, S. A., Plaetinck, G., Devos, R., Van der Heyden, J., and Guisez, Y. (1997) A human leptin mutant induces weight gain in normal mice. *FEBS Lett.* **405**, 237–240 CrossRef Medline

65. Shabana and Hasnain, S. (2016) The p.N103K mutation of leptin (LEP) gene and severe early onset obesity in Pakistan. *Biol. Res.* **49**, 23 CrossRef Medline

66. Kratzsch, J., Berthold, A., Lammert, A., Reuter, W., Keller, E., and Kiess, W. (2002) A rapid, quantitative immunofunctional assay for measuring human leptin. *Horm. Res.* **57**, 127–132 Medline

67. Khan, S., and Vihinen, M. (2007) Spectrum of disease-causing mutations in protein secondary structures. *BMC Struct. Biol.* **7**, 56 CrossRef Medline

68. Noel, J. K., Levi, M., Raghunathan, M., Lammert, H., Hayes, R. L., Onuchic, J. N., and Whitford, P. C. (2016) SMOG 2: a versatile software package for generating structure-based models. *PLoS Comput. Biol.* **12**, e1004794 CrossRef Medline

69. Finn, R. D., Coggill, P., Eberhardt, R. Y., Eddy, S. R., Mistry, J., Mitchell, A. L., Potter, S. C., Punta, M., Qureshi, M., Sangrador-Vegas, A., Salazar, G. A., Tate, J., and Bateman, A. (2016) The Pfam protein families database: towards a more sustainable future. *Nucleic Acids Res.* **44**, D279 –D285 CrossRef Medline

70. Gierut, A. M., Niemyska, W., Dabrowski-Tumanski, P., Sulkowski, P., and Sulkowska, J. I. (2017) PyLasso: a PyMOL plugin to identify lassos. *Bioinformatics* **33**, 3819 –3821 CrossRef Medline